Blackstone puts $250M into Anagram to tackle cystic fibrosis complication
Blackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on a little-known biotech seeking to drastically reduce the number of ...
Original Source
Read the full article at Endpoints →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.